SECAUCUS, N.J., June 1, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the William Blair 43rd Annual Growth Stock Conference. Sam Samad, Executive Vice President and CFO will discuss recent market developments and trends as well as the company's performance and strategy. The presentation is scheduled for Tuesday, June 6, 2023, at 4:20 p.m. Eastern Time.
The presentation will be webcast live during the conference and will be available on the company's investor relations page which can be accessed at ir.QuestDiagnostics.com. The Q&A breakout session will not be webcast live but will be available as a replay. The archived presentation and Q&A breakout session will both be available within 24 hours after the conclusion of the live event and will remain available until July 4, 2023.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
Last Trade: | US$168.82 |
Daily Change: | 2.40 1.44 |
Daily Volume: | 1,409,082 |
Market Cap: | US$18.840B |
January 08, 2025 December 03, 2024 October 23, 2024 October 22, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load